SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-20-018121
Filing Date
2020-03-11
Accepted
2020-03-11 16:50:46
Documents
1
Period of Report
2020-02-19

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4262
  Complete submission text file 0001209191-20-018121.txt   5661
Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Issuer) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O PREVAIL THERAPEUTICS INC. 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address
Abeliovich Asa (Reporting) CIK: 0001778476 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38939 | Film No.: 20705911